Navigation Links
Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
Date:3/11/2008

; William D. Kolton, M.D. of San Diego, California; Linda Roman, M.D. of the University of Southern California (USC); Michael L. Twede, M.D. of the Salt Lake Women's Center in Sandy, Utah; and Mark T. Saunders, M.D. at the Mt. Timpanogos Women's Healthcare/Physician's Research in Pleasant Grove, Utah.

About New HspE7:

The Company's lead candidate, new HspE7 (HspE7 + Poly-ICLC), is a novel therapeutic candidate intended for the treatment of precancerous and cancerous lesions caused by the human papillomavirus (HPV), one of the most common sexually transmitted diseases in the world. New HspE7 contains the novel CoVal(TM) fusion protein, HspE7 co-administered with the adjuvant, Poly-ICLC, a toll-like receptor-3 (TLR3) agonist adjuvant. An adjuvant is a substance added to vaccines to improve immune responses against target antigens. HspE7 is derived from Nventa's proprietary CoVal(TM) fusion platform, which uses recombinant DNA technology to covalently fuse stress proteins to target antigens, thereby stimulating cellular immune system responses. Nventa is developing new HspE7 for multiple indications.

About Nventa Corporation:

Nventa is developing innovative therapeutics for the treatment of viral infections and cancer, with a focus on diseases caused by the human papillomavirus (HPV). The corporation is publicly traded on the Toronto Stock Exchange under the symbol NVN. For more information about Nventa, please visit http://www.nventacorp.com.

This press release contains statements which may constitute forward-looking information under applicable Canadian securities legislation or forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking statements or information may include financial and other projections as well as statements regarding the Company's future plans, objectives, performance, revenues, gro
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
2. VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
3. Spectranetics Enrolls First Patient in PATENT Trial for the Treatment of Instent Restenosis
4. Ception Therapeutics Initiates Phase II/III Clinical Trial for Its Lead Product Reslizumab in Eosinophilic Esophagitis (EE) in Children
5. Pharmacopeia Initiates Second Phase 2 Hypertension Study with PS433540 (DARA)
6. Phosphagenics Initiates U.S. Clinical Trials for Its Topical Retinoic Acid
7. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
8. Tigris Pharmaceuticals Initiates Phase I Study of AFP-464 in Patients with Solid Tumors
9. Nuvelo Initiates Phase 1 Clinical Trial of Thrombin Inhibitor, NU172
10. Northwestern Memorial Transplant Program Initiates New Study
11. Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... -- Research and Markets  has announced the addition of ... report to their offering. The Central Nervous ... largest segments of pharmaceuticals industry. The numbers of CNS disorders ... were unable to meet the market requirements. There has been ... especially over the past two decades. The market for CNS ...
(Date:8/29/2014)... Vittamed Corporation , a neurodiagnostics medical device company based in ... (Teo) Forcht Dagi , MD, DmedSc, MPH, MBA, FACS, FRCSEd ... " Teo Forcht Dagi is an experienced leader ... capital," said Remis Bistras , President and CEO of ... and entrepreneurial expertise to our Board." Dr. Dagi ...
(Date:8/29/2014)... -- Research and Markets has announced the ... 2014-2018" report to their offering. ... results in demyelination, axonal transection, and neurodegeneration. The myelin ... the immune system, which targets neurons within the central ... in which the damage of the myelin sheath causes ...
Breaking Medicine Technology:US CNS Disorders Drug Pipeline Insight 2014 2Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3
... June 29 Noting that only about 200 of the nearly 7,000 ... today called for a Food and Drug Administration (FDA) statement of policy on regulation ... , NORD also urged ... of medicines for rare disorders. , , ...
... , DAYTON and CINCINNATI, Ohio , June 29 ... with Stipkala LLC, was an invited speaker and panel discussion participant at ... in Dayton, Ohio June 16-19, 2010 .  The 2010 ... new technologies in addition to traditional chemical disciplines.   , ...
Cached Medicine Technology:NORD Calls for Statement of Policy on Orphan Drug Development 2Dr. Harry J. Guttman, Esq. Invited Speaker at 2010 Central Regional Meeting of the American Chemical Society 2
(Date:9/1/2014)... (PRWEB) September 02, 2014 Top10BestSEOHosting.com is ... recently compared many top web hosting companies and announced ... hosting suppliers in August. , GreenGeeks ( http://www.greengeeks.com/cgi-bin/affiliates/clickthru.cgi?id=seohosts ... from the USA. The company has a lot of ... always get great products at low rates. , ...
(Date:9/1/2014)... was associated with mental health and substance use ... protect teens from the consequences of cyberbullying and ... Author: Frank J. Elgar, Ph.D., of McGill University, ... in 5 adolescents has experienced recent online bullying ... risk of mental health problems in teens as ...
(Date:9/1/2014)... 01, 2014 Liver is the largest organ ... that helps the body in barring itself from poisons, helps ... energy. Liver also plays many important functions such as protein ... , Many illnesses can affect the liver, an organ ... cage on the right side of the abdomen, reducing its ...
(Date:9/1/2014)... The B-cell non-Hodgkin’s Lymphoma (NHL) treatment ... markets (the US, France, Italy, Germany, Spain and the ... by 2018. , The competitive landscape in the B-cell ... and the UK is poised to undergo a dramatic ... four largest B-cell NHL indications, which includes Diffuse Large ...
(Date:9/1/2014)... D.C. (PRWEB) September 01, 2014 The ... pleased to announce that Dawn Bazarko, DNP, MPH, RN, ... Fellows of the American Academy of Nursing. They will ... MBA, RN-BC, CCM, FACHE, whose induction we reported last ... October 18, 2014, during the 2014 American Academy of ...
Breaking Medicine News(10 mins):Health News:The Best Reseller Hosting Suppliers in August Released by Leading Review SiteTop10BestSEOHosting.com 2Health News:Family dinners good for teens' mental health, could protect from cyberbullying 2Health News:Family dinners good for teens' mental health, could protect from cyberbullying 3Health News:Global Liver Diseases and Therapies Market- The Key Basics by Transparency Market Research 2Health News:Global Liver Diseases and Therapies Market- The Key Basics by Transparency Market Research 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 2Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 4Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 2Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 3Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 4
... in the early detection of coronary heart disease (CHD) between ... 45-64 have undetected or silent myocardial infarctions, suggesting a general ... a doctors gender may hinder early hinder early diagnosis of ... by Dr Ann Adams of Warwick Medical School at the ...
... indoor mould improves the symptoms of people with asthma. , ... is among the highest in the world, with 260,000 people ... admissions for adults 12 per cent more than anywhere else ... asked patients with asthma living in two areas of South ...
... Memry Corporation,(Amex: MRY ), a leading provider ... announced today that it will release its fiscal,fourth quarter ... 17,after the market closes. The company will host ... of the management team on Tuesday, September 18 at ...
... ... Refined Cats, Palates, CHELMSFORD, Mass., Sept. 5 ... natural food and treats for pets,is launching a NEW offering for ... real,seafood and poultry morsels and an array of fresh fruits and ...
... choices for older Americans, researchers find , WEDNESDAY, Sept. ... that charge higher co-pays for brand name or non-preferred ... peers who have a flat co-pay for all prescription ... a tough decision for older Americans: Spend more or ...
... Medical,Organizations Growing Rapidly with Thousands of Community Members ... introduced Lance Hill,as the new CEO of the ... physicians, researchers, and medical organizations worldwide. Members,use Within3,s ... as a,professional tool, where they can develop their ...
Cached Medicine News:Health News:Research says doctor's gender may hinder early diagnosis of heart disease in women 2Health News:Research says doctor's gender may hinder early diagnosis of heart disease in women 3Health News:Memry Corporation Announces Fiscal Fourth Quarter and 2007 Year End Earnings Release and Conference Call 2Health News:Finicky Felines Award Four Stars to New Wellness(R) Healthy Indulgence Everyday Entrees 2Health News:Finicky Felines Award Four Stars to New Wellness(R) Healthy Indulgence Everyday Entrees 3Health News:High Co-Pays Cause Seniors to Go Without Meds 2Health News:Cleveland-based Health Care Tech Company Within3 Names New CEO 2
... Mini low cost Incubators. Bench top ... excellent incubation results. Aluminum lined chamber ... and I104025 incubators contain removable perforated ... easy decontamination. Thermometer port on top ...
Binocular indirect ophthalmic lenses. Pediatric ophthalmoscopy / vetinary applications....
Binocular indirect ophthalmic lenses. Small pupil diagnosis & treatment....
Binocular indirect ophthalmic lenses. General diagnosis & treatment....
Medicine Products: